Intellia To Take On Pfizer Blockbuster With Gene-Editing Therapy
Aims To Challenge Vyndaqel
After achieving a landmark in gene-editing with NTLA-2001, Intellia moves to expand its reach into a larger market.
You may also be interested in...
The company presented 18-month data at a conference that it thinks will support strong uptake. European regulators required the 18-month data for filing; an FDA decision based on 9-month data is expected in April.
The news desert over the holidays meant that any Phase III clinical study announcement would be closely examined. Unfortunately, BridgeBio’s shock Phase III failure was made worse by elusive explanations.
GSK now looks free to pursue its ‘Plan A’ for the consumer division, but activist investors may push for a new bidder to be found.